{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T06:30:28Z","timestamp":1791095428270,"version":"4.1.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["Cinque per mille (5Xmille 2019 grant 5M-2019\\u201323680413)"],"award-info":[{"award-number":["Cinque per mille (5Xmille 2019 grant 5M-2019\\u201323680413)"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["Ricerca Corrente"],"award-info":[{"award-number":["Ricerca Corrente"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["PNRR-MR1\\u20132023\\u201312378412"],"award-info":[{"award-number":["PNRR-MR1\\u20132023\\u201312378412"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008385","name":"Cystic Fibrosis Research Foundation","doi-asserted-by":"publisher","award":["FFC #10\/2021"],"award-info":[{"award-number":["FFC #10\/2021"]}],"id":[{"id":"10.13039\/501100008385","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jcf.2026.05.015","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T11:34:01Z","timestamp":1780572841000},"page":"918-924","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Vanzacaftor-Tezacaftor as an alternative therapeutic resource for the ETI-Resistant L467F-F508del Allele: Ex vivo prediction and exploratory clinical assessment"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9740-1171","authenticated-orcid":false,"given":"Valeria","family":"Capurro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Pesce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2483-5374","authenticated-orcid":false,"given":"Federico","family":"Cresta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8565-4393","authenticated-orcid":false,"given":"Cristina","family":"Pastorino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7858-593X","authenticated-orcid":false,"given":"Alice","family":"Mantero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3761-1916","authenticated-orcid":false,"given":"Valeria","family":"Tomati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7497-9165","authenticated-orcid":false,"given":"Valeria","family":"Dacc\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Claut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetta","family":"Fabrizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Zara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Castellani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5161-1720","authenticated-orcid":false,"given":"Nicoletta","family":"Pedemonte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.jcf.2026.05.015_bib0001","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor-Ivacaftor for Cystic fibrosis with a single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jcf.2026.05.015_bib0002","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/humu.23389","article-title":"Cis variants identified in F508del complex alleles modulate CFTR channel rescue by small molecules","volume":"39","author":"Baatallah","year":"2018","journal-title":"Hum Mutat"},{"issue":"Suppl 1","key":"10.1016\/j.jcf.2026.05.015_bib0003","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/j.jcf.2019.12.008","article-title":"The influence of CFTR complex alleles on precision therapy of cystic fibrosis","volume":"19","author":"Chevalier","year":"2020","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10.1016\/j.jcf.2026.05.015_bib0004","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.3390\/ijms23063175","article-title":"The L467F-F508del complex Allele hampers pharmacological rescue of mutant CFTR by Elexacaftor\/Tezacaftor\/Ivacaftor in cystic fibrosis patients: the value of the ex vivo nasal epithelial model to address non-responders to CFTR-modulating drugs","volume":"23","author":"Sondo","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.jcf.2026.05.015_bib0005","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S2213-2600(24)00407-7","article-title":"Vanzacaftor-tezacaftor-deutivacaftor for children aged 6-11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial","volume":"13","author":"Hoppe","year":"2025","journal-title":"Lancet Respir Med"},{"issue":"3","key":"10.1016\/j.jcf.2026.05.015_bib0006","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S2213-2600(24)00411-9","article-title":"Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials","volume":"13","author":"Keating","year":"2025","journal-title":"Lancet Respir Med"},{"issue":"6","key":"10.1016\/j.jcf.2026.05.015_bib0007","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S2213-2600(22)00504-5","article-title":"Safety and efficacy of vanzacaftor-tezacaftor-deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials","volume":"11","author":"A. Z","year":"2023","journal-title":"Lancet Respir Med"},{"issue":"2","key":"10.1016\/j.jcf.2026.05.015_bib0008","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1124\/jpet.117.241497","article-title":"Altering metabolic profiles of drugs by precision deuteration 2: discovery of a deuterated analog of ivacaftor with differentiated pharmacokinetics for clinical development","volume":"362","author":"Harbeson","year":"2017","journal-title":"J Pharmacol Exp Ther"},{"issue":"24","key":"10.1016\/j.jcf.2026.05.015_bib0009","doi-asserted-by":"crossref","first-page":"6063","DOI":"10.1111\/bph.70176","article-title":"In silico, in vitro and ex vivo characterization of cystic fibrosis transmembrane conductance regulator pathogenic variants localized in the fourth intracellular loop and their rescue by modulators","volume":"182","author":"Pesce","year":"2025","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jcf.2026.05.015_bib0010","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1661417","article-title":"Beyond Trikafta: new models to assess tissue dependent rescue of N1303K-CFTR","volume":"16","author":"Pranke","year":"2025","journal-title":"Front Pharmacol"},{"issue":"4","key":"10.1016\/j.jcf.2026.05.015_bib0011","doi-asserted-by":"crossref","DOI":"10.1002\/mgg3.1656","article-title":"Ex vivo model predicted in vivo efficacy of CFTR modulator therapy in a child with rare genotype","volume":"9","author":"Terlizzi","year":"2021","journal-title":"Mol Genet Genomic Med"},{"key":"10.1016\/j.jcf.2026.05.015_bib0012","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1494327","article-title":"Pharmacological rescue of the G85E CFTR variant by preclinical and approved modulators","volume":"15","author":"Tomati","year":"2024","journal-title":"Front Pharmacol"},{"issue":"3","key":"10.1016\/j.jcf.2026.05.015_bib0013","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.jcf.2022.12.005","article-title":"Rescue by elexacaftor-tezacaftor-ivacaftor of the G1244E cystic fibrosis mutation's stability and gating defects are dependent on cell background","volume":"22","author":"Tomati","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"2","key":"10.1016\/j.jcf.2026.05.015_bib0014","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.stem.2016.05.012","article-title":"Dual SMAD signaling inhibition enables long-term expansion of diverse epithelial basal cells","volume":"19","author":"Mou","year":"2016","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.jcf.2026.05.015_bib0015","article-title":"Correlating genotype with phenotype using CFTR-mediated whole-cell Cl(-) currents in human nasal epithelial cells","author":"Noel","year":"2021","journal-title":"J Physiol"},{"key":"10.1016\/j.jcf.2026.05.015_bib0016","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/978-1-61779-117-8_2","article-title":"High-throughput screening of libraries of compounds to identify CFTR modulators","volume":"741","author":"Pedemonte","year":"2011","journal-title":"Methods Mol Biol"},{"issue":"3","key":"10.1016\/j.jcf.2026.05.015_bib0017","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1124\/jpet.109.154146","article-title":"Mutation-specific potency and efficacy of cystic fibrosis transmembrane conductance regulator chloride channel potentiators","volume":"330","author":"Caputo","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"issue":"7","key":"10.1016\/j.jcf.2026.05.015_bib0018","doi-asserted-by":"crossref","first-page":"6576","DOI":"10.3390\/ijms24076576","article-title":"Clinical consequences and functional impact of the rare S737F CFTR variant and its responsiveness to CFTR modulators","volume":"24","author":"Terlizzi","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.jcf.2026.05.015_bib0019","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jcf.2018.05.010","article-title":"Combination potentiator ('co-potentiator') therapy for CF caused by CFTR mutants, including N1303K, that are poorly responsive to single potentiators","volume":"17","author":"Phuan","year":"2018","journal-title":"J Cyst Fibros"},{"issue":"246","key":"10.1016\/j.jcf.2026.05.015_bib0020","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008680","article-title":"Potentiator ivacaftor abrogates pharmacological correction of DeltaF508 CFTR in cystic fibrosis","volume":"6","author":"Cholon","year":"2014","journal-title":"Sci Transl Med"},{"issue":"246","key":"10.1016\/j.jcf.2026.05.015_bib0021","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008889","article-title":"Some gating potentiators, including VX-770, diminish DeltaF508-CFTR functional expression","volume":"6","author":"Veit","year":"2014","journal-title":"Sci Transl Med"},{"issue":"9","key":"10.1016\/j.jcf.2026.05.015_bib0022","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1164\/rccm.201903-0696ED","article-title":"Unraveling the CFTR function-phenotype connection for precision treatment in Cystic Fibrosis","volume":"199","author":"Zemanick","year":"2019","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199326016383?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199326016383?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T20:37:17Z","timestamp":1790282237000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199326016383"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1569199326016383"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2026.05.015","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vanzacaftor-Tezacaftor as an alternative therapeutic resource for the ETI-Resistant L467F-F508del Allele: Ex vivo prediction and exploratory clinical assessment","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2026.05.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}